StocksMedium•5 November 2026•
1 min read
Hikma Pharmaceuticals Raises 2026 Branded Business Revenue Outlook
Key Facts
1Hikma Pharmaceuticals narrowed its full-year 2026 core operating profit outlook.
2The company raised its revenue growth expectations for its Branded business segment.
Hikma Pharmaceuticals narrowed its full-year 2026 core operating profit outlook. Benzinga reported that the company also raised its revenue growth expectations for its Branded business segment, following updated performance assessments for the current fiscal year.
The revision reflects continued growth within the company's branded drugs division. Hikma Pharmaceuticals issued the update as part of its financial guidance for the remainder of 2026, aiming to refine its profit expectations while strengthening sales targets in key business areas.